G-PUR® for Reduced Dietary Fumonisin Bioavailability

Overview

This prospective, placebo-controlled, randomized, monocentric, double-blind, crossover study in healthy volunteers aims to assess the effect of a single dose of 2 g G-PUR® on bioavailability of dietary fumonisin and to evaluate safety and tolerability.

Full Title of Study: “A Randomized, Placebo-controlled, Double-blind, Cross-over Study to Evaluate the Effect of G-PUR® on Dietary Fumonisin Bioavailability”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Prevention
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: November 4, 2020

Interventions

  • Device: 2.0g G-PUR®
    • Oral administration (Intervention period I)
  • Device: 2.0g G-PUR®
    • Oral administration (Intervention period II)
  • Other: Placebo
    • Intervention period I
  • Other: Placebo
    • Intervention period II

Arms, Groups and Cohorts

  • Experimental: 2.0g G-PUR® oral – Placebo
  • Experimental: Placebo – 2.0g G-PUR® oral

Clinical Trial Outcome Measures

Primary Measures

  • The bioavailability of fumonisin is estimated based on the concentration of urinary biomarkers FB1 and FB2
    • Time Frame: 24 hours

Secondary Measures

  • Incidence of (serious) adverse device effects
    • Time Frame: 19 days
  • Urinary biomarkers FB1 and FB2 (separately and sum of FB1 and FB2)
    • Time Frame: 24 hours

Participating in This Clinical Trial

Inclusion Criteria

1. Healthy male and female subjects 2. Age 18-55 years 3. BMI 17-27 4. Subjects are in good clinical and mental health as established by medical history and physical examination 5. Subject understands the scope of the study and agrees to strictly adhere to the study related diet plan 6. Written informed consent Exclusion Criteria:

1. Pregnancy or breastfeeding. 2. Lack of willingness or capacity to co-operate appropriately 3. Regular use of medications in the previous 2 months (except oral contraception) 4. History of malignancies within the past two years or on current anticancer treatment 5. History of gastrointestinal pathology such as clinically relevant gastritis, gastric ulcers, inflammatory bowel disease, chronic constipation 6. History of diarrhoea within the past 14 days of screening 7. History of gastrointestinal surgery with exception of appendectomy 8. History of any chronic liver disease 9. History of autoimmune disease requiring treatment within the past two months of screening 10. Known symptomatic food allergies 11. Active infection (including HIV and hepatitis B or C), or abnormalities in laboratory testing, vital signs, or physical examination 12. Hypersensitivity to aluminium and/or silicon 13. Chronic renal disease requiring dialysis 14. Alcohol, cigarette or drug abuse 15. Presence of any condition that impacts compliance with the study procedures 16. Use of any investigational or non-registered product (drug or device) within 30 days preceding the first study product administration, or planned use during the study period 17. Employee at the study site, spouse/partner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to the sponsor

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Glock Health, Science and Research GmbH
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Michael Wolzt, Prof.Dr., Principal Investigator, Department of Clinical Pharmacology, Medical University of Vienna

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.